Patient-Reported Outcomes in Eosinophilic Esophagitis and Achalasia. by Schoepfer, Alain et al.
Patient-Reported Outcomes
in Eosinophilic Esophagitis
and Achalasia
Alain Schoepfer, MD1,*
Alex Straumann, MD2
Ekaterina Safroneeva, PhD3
Address
*,1Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire
Vaudois, Rue de Bugnon 44, 07/2409, 1011, Lausanne, Switzerland
Email: alain.schoepfer@chuv.ch
2Swiss EoE Clinic, Praxis Römerhof, Olten, Switzerland
3Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Keywords Achalasia I Eosinophilic esophagitis I Clinician-reported outcome I Patient-reported outcome I
Instrument I Questionnaire I Symptoms I Quality of life
Opinion Statement
The activity of a particular esophageal disease, such as eosinophilic esophagitis
(EoE) or achalasia, can be evaluated using clinician-reported outcome (ClinRO)
measures assessing various endoscopic, histologic, functional, and laboratory
findings, and patient-reported outcome (PRO) measures. The patient-reported
outcome (PRO) measures are those that are designed to be self-reported by
patients. Commonly used PRO instruments include those that assess symptom
severity, health-related quality of life, “general” quality of life, or health status.
Regulatory authorities increasingly rely on PRO measures to support labeling
claims for drug development. Validated PRO measures for various esophageal
diseases are needed in order to unify and standardize the way disease activity
is assessed, define clinically meaningful endpoints for use in interventional and
observational studies, compare the efficacy/effectiveness of various therapies,
and optimize therapeutic algorithms for management of these diseases. This
article reviews commonly used PRO instruments designed to assess symptom
severity and quality of life in adult patients with EoE and achalasia.
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Introduction
How to measure the activity of esophageal diseases
The activity of a particular esophageal disease can be
assessed by the means of patient-reported outcome
(PRO) and clinician-reported outcome (ClinRO) mea-
sures. The concept is depicted in Fig. 1.
The PRO is an “umbrella term” that, among other
things, encompasses various measures of symptom se-
verity, functioning (disability), health status, health-
specific quality of life, “general” quality of life, and
general health perceptions. PRO instruments assess ei-
ther a single underlying characteristic of a disease, in
which case these instruments are termed unidimension-
al, or multiple constructs, in which case the instruments
are termed multidimensional. Measures of symptom
severity focus on a particular or several disease-related
impairments. Measures of disability assess the degree of
impairment that manifests itself when performing vari-
ous daily activities, such as personal care, and locomo-
tion. Health-specific quality of life measures tend to be
multidimensional instruments that assess various as-
pects related to impairment and/or disability inherent
to a particular disease. These instruments allow the users
to stratify the subjects into various “health status” or
“clinical states” based on responses to the items that
query relevant information on patients’ perception of
health. As such, these instruments enable the compari-
sons between groups of patients with a particular disease
that are treated by different therapeutic regimens and
allow for monitoring of changes in “health status” or
“clinical state” of a given patient [1]. In contrast, the
“general” quality of life instruments evaluate the
patients’ ability to fulfill their needs and assess the im-
pact of a restriction or impairment on emotional well-
being. These instruments help researchers to compare
across different conditions and populations [1].
In esophageal diseases, endoscopic, histologic, and
laboratory findings, as well as other aspects of gastroin-
testinal physiology, such as esophageal motility (as
assessed by manometry) or gastric acid reflux (as
assessed by impedance-pH-metric study), are evaluated
using ClinRO measures.
The development and validation of PRO instruments
is an iterative process that has been described in a posi-
tion paper by the US Food andDrug Administration (US
FDA) [2]. In the first phase, items are generated using
patient input. The generated items are incorporated into
an instrument (questionnaire), which is evaluated in a
first and then validated in a second patient group. Dur-
ing the entire process, patient feedback is sought on
numerous occasions. The instrument should be content
valid, which means that it measures the disease-
associated dimensions relevant to the patients, and re-
sponsive to change in a health status. The US FDA and
the European Medicines Agency (EMA) put a particular
emphasis on the use of validated PRO instruments in
the trials of medical products in order to support label-
ling claims [2]. Interestingly, the EMA more frequently
grants PRO label claims when compared to the US FDA
[3].
Why do we need validated PRO instruments for
assessment of the activity of esophageal diseases? First,
these instruments help the users to standardize the lan-
guage of disease activity assessment. Second, such vali-
dated PRO instruments and respective scores serve as
endpoints in clinical trials and observational studies.
The use of these standardized measures facilitates the
comparison of the efficacy/effectiveness of various ther-
apies and aids in optimization of therapeutic algorithms
used to identify the appropriate therapy for patients.
Should the activity of esophageal diseases mainly be
measured based solely on PRO, or ClinRO measures, or
a combination of both? When assessing activity of any
disease, it is important to take into account PRO, so long
the disease-inherent alterations lead to generation of
symptoms and changes in psychosocial functioning that
can be reliably assessed by PROmeasures. Similarly, it is
important to take into account ClinRO measures, if
these assess biologic findings that may serve as
Fig. 1. Assessing activity of esophageal disease by patient-
reported outcome (PRO) or clinician-reported outcome
(ClinRO) measures. QoL quality of life.
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biomarkers for estimation of disease severity. We have
recently described this concept elsewhere [4]. In esoph-
ageal diseases, such as EoE or GERD or achalasia, both
PRO and ClinRO measures should be assessed to get a
complete picture on disease activity overall.
In this review, the currently available PRO instru-
ments assessing symptom severity and quality of life in
adults with EoE and achalasia are discussed. A system-
atic review of PRO instruments for assessment of gastro-
esophageal reflux disease (GERD) activity has recently
been published [5••].
PRO instruments for use in eosinophilic esophagitis
patients
Eosinophilic esophagitis (EoE) emerged as distinct dis-
ease in the early 1990s [6•, 7•]. In industrialized coun-
tries, an incidence rate of about 1 new patient per 10,000
inhabitants per year and prevalence rate of approximate-
ly 1 patient per 2000 inhabitants is observed [8–11]. In
the consensus guidelines first published in 2007 and
updated in 2011, the experts defined EoE as “a chronic,
immune/antigen-mediated, esophageal disease, charac-
terized clinically by symptoms related to esophageal
dysfunction and histologically by eosinophil-
predominant inflammation” [12••, 13••]. Given the
fact that esophageal eosinophilia can be caused by other
diseases, such as GERD, Crohn’s disease, or achalasia,
these should be excluded prior to establishing the EoE
diagnosis. Historically, different non-EoE-specific or
nonvalidated instruments have been used in clinical
trials and observational studies. As a consequence, rela-
tionship between EoE symptom severity and histologic
activity was a matter of much controversy, as dissocia-
tion between severity symptoms and histologic findings
have been described in some [14–16], but not other
studies [17, 18]. The validated instruments for assess-
ment of the severity of various EoE-specific symptoms
and biologic findings as well as EoE-specific quality of
life have recently become available.
When assessing symptom severity in EoE patients,
one has to keep in mind a few particularities. First, EoE
symptom presentation is age-dependent [19]. Feeding
difficulties and failure to thrive are symptoms more
typical of infants and toddlers, while vomiting and ab-
dominal pain are symptoms more characteristic of
school-aged children. Dysphagia and food impactions
are principal symptoms of adolescent and adult EoE
patients. Second, patients need to recall their symptoms
over a defined time period. Although regulatory author-
ities emphasize the importance of using daily electronic
diaries in the context of clinical trials sponsored by
pharmaceutical companies, the use of these diaries
may not be entirely feasible in the context of long-term
observational studies. As such, other recall periods must
be considered. Third, the severity of dysphagia and be-
havioral adaptations to living with dysphagia may vary
depending on the consistency of foods consumed by the
patients. Therefore, instrument developers should at-
tempt to capture the full spectrum of various behavioral
adaptations and dysphagia severity by separately exam-
ining these for each distinct food consistency.
An overview of the available PRO instruments for use
in adult EoE patients is provided below.
EoE activity index (EEsAI) PRO instrument
In 2014, Schoepfer et al. described the development and
validation of the EoE activity index (EEsAI) PRO instru-
ment (copyrighted by the University of Bern, Switzerland)
[20••]. The work was carried out by the international
EEsAI study group in line with the recommendations of
the US FDA [2]. Multivariable linear regression analysis
and analysis of variance with patient global assessment as
dependent variable and distinct symptoms as indepen-
dent variables were used to develop a PRO score by
quantifying the extent to which symptoms explained the
variability in patient global assessment. The EEsAI PRO
instrument was evaluated in a group of 153 adult EoE
patient and validated in the groupof another 120patients.
The EEsAI PRO score of 0 indicates lack of EoE-specific
symptoms, while a score of 100 points indicates most
severe symptoms. The EEsAI PRO instrument consists of
the five following components: frequency of dysphagia
episodes, duration of dysphagia episodes, pain when
swallowing, severity of dysphagia occurring when eating
foods of various consistencies, and behavioral adapta-
tions, such as avoiding distinct food due to EoE or cutting
food into small pieces. A median of 8 min is required for
instrument completion. Patients deemed the instrument
as easy to complete and capturing most of their EoE-
related complaints (content validity) [20••]. The EEsAI
PRO instrument is available with a symptom recall period
of 7 days and 24 hours. The responsiveness of the instru-
ment is currently evaluated in a number of clinical trials.
Dysphagia symptom questionnaire
In 2013, the development of the dysphagia symptom
questionnaire (DSQ) carried out in collaboration with
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Meritage Pharma, Inc. (copyright holder) was published
by Dellon et al. [21••]. The DSQ is an electronic daily
diary (symptom recall period of 24 h) consisting of three
items that report on solid-food-avoidance days, dyspha-
gia days, and actions taken to resolve dysphagia episode.
At the time of the publication, the food described as solid
was not actually specified. The scoring algorithm is ex-
pert-based. A score of 0 indicates lack of dysphagia, while
a score of 5 points indicates severe dysphagia. The field
trial was completed by adult (n=18) and adolescent
(n=17) EoE patients. The DSQ score has strong positive
association with the number of dysphagia days (R=0.96,
PG0.001). The instrument was shown to be content-
valid and is currently evaluated in a number of clinical
trials (personal communication).
Straumann dysphagia index instrument
Nonvalidated, the EoE-specific Straumann dysphagia
index (SDI) instrument for adults with EoE was first
used to assess symptom severity in a randomized, pla-
cebo-controlled trial evaluating the efficacy of swallowed
topical corticosteroids [22]. The measure and the scoring
algorithm (score ranges from 0 to 9 points) were devel-
oped by a physician (AS). The SDI assesses frequency and
intensity of dysphagia events; neither dysphagia caused
by foods of various consistencies nor behavioral adapta-
tions to living with dysphagia are evaluated. Responsive-
ness, defined as a decrease in 3 or more points from the
baseline score, was demonstrated in this trial [22].
Mayo dysphagia questionnaire
Grudell and coworkers published the paper on the de-
velopment and validation of the Mayo dysphagia ques-
tionnaire (MDQ) [23]. TheMDQ is designed to evaluate
dysphagia severity in adult patients affected by different
esophageal diseases. This non-EoE-specific PRO instru-
ment consists of the 28 items that query the following:
frequency and severity of dysphagia (17 items), con-
comitant allergies (3 items), the use of acid-suppressive
medication (3 items), past esophageal surgery (2 items),
presence of GERD (1 item), past esophageal dilations (1
item), and overall duration of trouble swallowing (1
item). The MDQ evaluates dysphagia severity and be-
havioral adaptations to living with dysphagia (food
modification and time to eat a regular meal) in the
context of consuming foods of different consistencies.
The MDQ, 30-day version (a 30-day recall period), has
shown to be reliable and was validated in a large group
of patients experiencing dysphagia [24]. On average,
patients take 10 min to complete the MDQ, 30-day
version. The instrument is also available with a recall
period of 2 weeks (MDQ, 2-week version) [14].
Instruments for assessment of quality of life in adult
EoE patients
Adult EoE quality of life instrument
In 2011, Taft and coworkers published a paper describ-
ing the development of EoE-specific quality of life mea-
sure for adults (EoO-QOL-A; copyrighted by Northwest-
ern University, Chicago, IL, USA) [25••]. Two hundred
and one patients between ages of 18 and 70 years old
were enrolled into the study. By the use of qualitative
methods, authors examined the whole spectrum of the
EoE-specific concerns and their impact on quality of life.
The 37-item instrument is split into the five following
subscales: eating/diet impact, social impact, emotional
impact, disease anxiety, and choking anxiety. Patients
that do not undergo dietary therapy complete only 32
items. Authors chose a recall period of 7 days. The EoO-
QOL-A instrument was shown to be reliable (internal
consistency, split-half, and test-retest). The QoL score
closely correlated with symptom severity score as
assessed by the adult PRO instrument (r = 0.610,
pG0.001) [26].
PRO instruments for gastroesophageal reflux disease
An excellent systematic review on this topic has been published by Vakil and
coworkers in 2013 [5••]. Authors identified existing PRO instruments for
assessment of severity gastroesophageal reflux disease (GERD) symptoms and
evaluated whether these instruments have been developed in accordance with
regulatory requirements of US FDA and EMA (e.g., have been shown to be
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reliable [content, construct and test-retest, internal consistency], and responsive
to change) [27]. Of the identified instruments, 15 PRO instruments underwent
psychometric evaluation. Of these, eight instruments were developed to assess
severity of GERD symptoms, two were developed to diagnose GERD, four PRO
instruments were developed for both evaluation and diagnosis of GERD, and
one PRO instrument was designed to screen for the existence of GERD. Devel-
opers of only five of the PRO instruments followed most steps outlined in
regulatory guidance documents. These five instruments were also used as
endpoint measures in clinical trials. Nonetheless, the authors concluded that,
as of yet, none of the PRO instrument developed to date met all of the
regulatory requirements for an outcome instrument in GERD trials [5••].
PRO instruments for achalasia
Achalasia is a rare disorder characterized by a loss of peristalsis and a failure of the
lower esophageal sphincter (LES) relaxation with swallowing. An annual inci-
dence of approximately 1.6 patients/100,000 inhabitants and a prevalence of 10
patients per 100,000 inhabitants are observed [28]. Affected patients most often
suffer from dysphagia for solids and liquids and regurgitation of undigested food
or saliva [29, 30•]. A mean diagnostic delay (time interval from onset of first
symptoms to diagnosis) of 4.7 years was documented in adult achalasia patients
[31]. The PRO instruments used in achalasia are reviewed below.
Instruments for assessment of symptoms in adult achalasia patients
The most frequently used scores for clinical assessment in achalasia are the
Eckardt score and the Vantrappen classification.
Eckardt score
The Eckardt score evaluates the frequency or severity of the following compo-
nents: weight loss, dysphagia, retrosternal pain, and regurgitation [32, 33]. Each
item ranks from 0 to 3 points with the final score ranking from 0 to 12 points.
Clinical remission was defined as Eckardt score of 3 and less, persisting for at
least 6 months [34]. The modification of the Eckardt score was also published.
Specifically, chest pain was rescored on a scale from 0 to 4 (none, G monthly,
monthly, weekly, daily), such as the entire instrument scores up to a
maximum of 13 points [29]. Using this modified scale for chest pain, a
definition of clinical remission of 4 points or less points was proposed.
The scoring algorithm is physician-based. For the development of the
score no systematic patient input, as proposed by regulatory authorities,
was used. The score is completed by the caregiver during a structured
clinical interview. The score is also used for clinical staging of achalasia
with stages from 0 (Eckardt score 0–1) to 3 (Eckardt score 96). A
Korean group found no significant correlation between the Eckardt
symptom score and Eckardt dysphagia grade and radiologic indices of
achalasia severity [35]. The Eckardt symptom score significantly correlat-
ed with the esophagogastric junction distensibility as measured by the
functional lumen imaging probe (FLIP™) [36].
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Vantrappen classification
Similar to the Eckardt score, the Vantrappen classification is a physician-based
instrument [37]. Patients are interviewed about the frequency of esophageal
symptoms, such as dysphagia, regurgitation, and chest pain. Depending on
whether these symptoms occur never, occasionally, more than once a week, or
daily, a symptoms score on a scale of 0–3 is applied. The total score ranges from
0 to 9 points. Clinical remission was arbitrarily defined as a score of ≤2 and
failure of treatment (or relapse) as a score of ≥3 points. In a prospective trial
randomizing 25 achalasia patients to undergo pneumatic dilation and 25
patients to undergo myotomy, patients were assessed clinically using the
Eckardt score, the Vantrappen classification, as well as the Adam’s stages [38].
Authors noted a significant correlation between the Vantrappen classification
and the Eckardt score.
Achalasia symptom questionnaire
The achalasia symptom questionnaire (ASQ) was published in 2010. The ASQ
is a 11-itemmeasure designed to assess symptoms typical of achalasia [39]. For
the first nine items, the symptoms severity is assigned a score between 0 (better)
and 4 (worse). The symptoms severity queried in items 10 and 11 is assigned a
score between 0 and 1 and 0 and 3, respectively. The total ASQ score of 0
indicates the lack of achalasia symptoms, while a score of 67 points indicates
severe achalasia symptoms. Item selection and scoring algorithm are based on
physician input. Using the data from the group of 124 adult patients, the
authors developed a mathematical model to predict achalasia in order to fast-
track patient to manometric confirmation of the suspected diagnosis [39].
Other clinical scores for achalasia
Other physician-developed scores, such as the one described by Vaezi and
colleagues, exist [40]. The authors performed interviews in patients. The total
achalasia symptom score reaches a maximum of 15 points and is a sum of
dysphagia, regurgitation, and chest pain subscores. The frequency of each
symptom was graded on a scale from 0 to 5 (0=none; 1=once per month or
less; 2=once per week, up to 3–4 times a month; 3=2–4 times per week;
4=once per day; 5= several times per day). The authors found that timed
barium esophagogram better predicted the long-term success after pneumatic
dilation than symptom assessment [40].
In summary, all available scoring systems to assess symptoms in achalasiawere
developed without psychometric evaluation and most of them are completed by
caregivers during patient interviews. This stands in contrast to the current US FDA
guidelines for PROdevelopment [2]. Nevertheless, it is important to point out that
these scores were developed well before comprehensive guidelines on PRO devel-
opment and validation were published by regulatory authorities [2].
Instruments used to assess quality of life in adult achalasia patients
As mentioned previously, quality of life can be assessed either by health-related
quality of life measures that are specific for a given disease or by generic quality
of life. The following instruments exist for assessment of quality of life in adult
achalasia patients.
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Health-related quality of life score by Urbach
The authors conducted semi-structured interviews with achalasia patients
(n=7) and sought expert input to create a list of items for development
of disease-specific quality of life measure [41]. The instrument was
evaluated in a group of 70 patients. A ten-item instrument covered the
following domains: food tolerance, dysphagia-related behavioral modifi-
cations, pain, heartburn, distress, lifestyle limitation, and satisfaction.
The total score is calculated by summing the score for each item (lowest
score 10 points, highest score 31 points), where after these outcomes are
transformed to a 0–100 point scale. A lower score represents a better
health-related QoL. The instrument was reliable and showed construct
validity; however, it was not validated in the initial form [41].
Frankhuisen et al. translated the measure developed by Urbach and
coworkers into Dutch and validated it in a group of 171 achalasia
patients [42]. The instrument proved to be easy in use. Authors con-
cluded that this achalasia instrument was a reliable and valid measure
for comparison of different groups of achalasia patients [42].
Disease-specific health-related quality of life questionnaire for achalasia
The disease-specific health-related quality of life questionnaire for esoph-
ageal achalasia (AE-18) is a self-administered measure that has been
developed in a group of 104 patients and prospectively validated in a
second group of adult achalasia patients. The qualitative methodology
was published only in abstract form [43]. The instrument consists of 18
items encompassing the following four domains: physical functioning,
psychological functioning, social functioning, and sleep. Patients were asked to
provide the answers on a five-point Likert scale ranging from 1 (“always)” to 5
(“never”). Higher scores correspond to better quality of life. Scores for each
domain are calculated as the median of the scores of corresponding items. The
responsiveness of the AE-18 instrument was evaluated in 65 prospectively
included adult achalasia patients, of whom 47 were dilated and 18 underwent
laparoscopic Heller myotomy [44]. Following treatment, AE-18 global score
and subscales scores increased; changes in quality of life were associated with
improvement in symptoms.
SF-36® health survey
The SF-36 health survey is a generic outcome measure designed to
examine a person ’s perceived health status [45, 46]. The self-
administered instrument takes 5–10 min to complete. It includes a
multiitem scale that measures each of the following eight health con-
cepts: (1) physical functioning, (2) role limitations because of physical
health problems, (3) bodily pain, (4) social functioning, (5) general
mental health (psychological distress and psychological well-being), (6)
role limitations because of emotional problems, (7) vitality (energy/
fatigue), and (8) general health perceptions. Answers to each item are
scored. For each health concept, these scores are summed to produce
raw scale scores, which are then transformed to a 0–100 scale. Generic
quality of life in achalasia patients was evaluated in several studies.
Frankhuisen et al. found that many achalasia patients remain severely
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symptomatic after treatment and also suffer from decreased health-
related quality of life [47]. Liu et al. evaluated health-related quality of
life in 35 adult achalasia patients undergoing transoral endoscopic
myotomy (POEM) and found that, besides the safety and efficacy of
the procedure in the short-term run, it also relieved symptom severity
and improved health-related quality of life [48].
Conclusions and outlook
The first guidelines on the development and validation of PRO, reflecting the
opinion of regulatory authorities, were published in 2007. Before 2007, multi-
ple instruments have been developed to assess symptom severity and quality of
life in adult patients suffering from EoE and achalasia. It is clear that these
instruments did not incorporate all recommendations from regulatory
authorities that are currently regarded as mandatory to establish a label-
ing claim for the efficacy of a particular therapeutic intervention that is
measured by a given PRO instrument. For EoE, there are currently two
PRO instruments (the EEsAI PRO instrument and the Dysphagia Symp-
tom Questionnaire [DSQ]) for assessment of symptom severity available
that were developed according to the guidelines of regulatory authori-
ties. In addition, the EoO-QOL-A instrument was developed following
these guidelines and allows measurement of EoE-specific quality of life.
In achalasia, there is currently no PRO instrument available that was
developed according to the guidelines from regulatory authorities. Fur-
ther collaborative efforts between different stakeholders are needed in
order to define to what extent therapeutic success should be defined by
either PRO or biologic measures.
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